{"gene":"PCIF1","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2003,"finding":"PCIF1 contains a WW domain that directly and preferentially binds to the phosphorylated (hyperphosphorylated) CTD of RNA polymerase II (RNAP IIO) compared to unphosphorylated CTD, both in vitro and in vivo. PCIF1 and endogenous RNAP IIO co-localize in the cell nucleus.","method":"32P-labeled CTD probe screening of cDNA library, in vitro binding assay, co-immunoprecipitation, double immunofluorescence in HeLa cells","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal in vitro and in vivo binding assays with co-localization, replicated across multiple methods in the same study","pmids":["12565871"],"is_preprint":false},{"year":2004,"finding":"PCIF1 (also called SPOP) interacts with the C-terminus of PDX-1 both in vitro and in vivo, localizes to the nucleus in a speckled pattern, and inhibits PDX-1 transactivation of target gene promoters in a dose-dependent manner requiring critical amino acids in the PDX-1 C-terminus.","method":"Co-immunoprecipitation, yeast two-hybrid, reporter gene assays, immunofluorescence, overexpression in MIN6 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pulldown, Co-IP, reporter assay, localization) in a single rigorous study","pmids":["15121856"],"is_preprint":false},{"year":2006,"finding":"Within PCIF1, both the TRAF and POZ domains are required for physical and functional interaction with the C-terminus of PDX-1; the C-terminal domain of PCIF1 directs its nuclear localization. The human PDX-1 diabetes-associated mutation E224K disrupts PCIF1-mediated inhibition of PDX-1 transactivation. Inhibition occurs by a mechanism distinct from classical POZ domain recruitment of co-repressors/HDACs.","method":"Co-immunoprecipitation of endogenous proteins in MIN6 cells, domain deletion/mutation analysis, reporter gene assays","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 / Strong — endogenous Co-IP plus domain mutagenesis and functional reporter assay, multiple orthogonal methods","pmids":["17126328"],"is_preprint":false},{"year":2009,"finding":"PCIF1 negatively modulates RNA Pol II activity in vivo. In PCIF1-deficient chicken DT40 cells, Pin1 (a prolyl isomerase with overlapping CTD-binding specificity) is significantly upregulated. PCIF1 and Pin1 share overlapping subcellular localization and similar inhibitory effects on transcriptional activation by Pol II.","method":"PCIF1-knockout DT40 cell lines, reconstitution experiments, transcriptional reporter assays, subcellular localization studies","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with functional readout and reconstitution, single lab","pmids":["19682092"],"is_preprint":false},{"year":2010,"finding":"PCIF1 (SPOP) targets PDX-1 for ubiquitination and proteasomal degradation. Silencing of Pcif1 increases Pdx1 protein levels in cultured mouse β cells. Pcif1 heterozygosity normalizes Pdx1 protein levels in Pdx1+/- islets, improves glucose homeostasis, β cell function, and normalizes β cell mass by modulating β cell survival.","method":"siRNA knockdown, heterozygous mouse genetics, protein stability assays, ubiquitination assays, glucose tolerance tests, β cell mass measurements","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model plus in vitro ubiquitination assay, multiple orthogonal methods across cell and animal models","pmids":["20811152"],"is_preprint":false},{"year":2019,"finding":"PCIF1 (also called CAPAM) is a mRNA cap adenosine N6-methyltransferase that methylates adenosine when it is the first transcribed nucleotide of capped mRNAs.","method":"Review/summary citing identification of enzymatic activity (references original biochemical characterization studies)","journal":"Trends in biochemical sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Strong — review summarizing biochemical identification; mechanistic detail confirmed by multiple primary studies below","pmids":["30679132"],"is_preprint":false},{"year":2020,"finding":"PCIF1 is the mammalian cap-specific m6Am RNA methyltransferase responsible for N6-methylation of 2'-O-methyladenosine at the first transcribed position. Loss of PCIF1 in mice does not affect viability or fertility but reduces body weight. Transcriptome analyses support a role for cap-specific m6Am in stabilizing transcripts. Drosophila Pcif1 is catalytically dead but retains Ser5-phosphorylated CTD binding. Trypanosoma Pcif1 is an m6Am methylase contributing to hypermethylated cap4.","method":"Pcif1 knockout mice, transcriptome analysis, biochemical methyltransferase assay, phylogenetic/functional comparison across species","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo KO mouse model combined with transcriptomics and biochemical activity assays, multiple orthogonal methods","pmids":["32814042"],"is_preprint":false},{"year":2021,"finding":"PCIF1 efficiently modifies VSV mRNA cap structures to m7Gpppm6Am and attenuates the antiviral effects of interferon-β. PCIF1-dependent modification of VSV mRNA caps does not affect mRNA stability, translation, or viral infectivity, but specifically reduces the antiviral response. Cells lacking PCIF1 or expressing catalytically inactive PCIF1 show augmented inhibition of viral replication after IFN-β treatment. PCIF1 also modifies mRNA caps of rabies and measles viruses.","method":"Cell-based antiviral assays, in vitro biochemical methyltransferase assays, PCIF1 knockout cells, catalytically inactive PCIF1 mutant, mRNA stability/translation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution plus cell-based assays with catalytic mutant, multiple orthogonal methods in one rigorous study","pmids":["34266951"],"is_preprint":false},{"year":2021,"finding":"PCIF1 is recruited to promoters of a broad range of Pol II-transcribed genes, predominantly at transcription start sites, in a manner entirely dependent on transcriptional activity and Ser5-phosphorylation of the CTD. PCIF1 is mainly localized to transcriptionally active chromatin, suggesting cotranscriptional N6-methylation of the first adenosine of nascent mRNAs.","method":"Subcellular fractionation, immunofluorescence microscopy, chromatin immunoprecipitation (ChIP) in HeLa cells, transcription inhibition experiments","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, fractionation, and immunofluorescence with functional dependency experiments, multiple orthogonal methods","pmids":["33982754"],"is_preprint":false},{"year":2021,"finding":"HIV Vpr protein interacts with PCIF1 and induces PCIF1 ubiquitination and degradation, thereby reprogramming the host m6Am RNA methylome. PCIF1 methyltransferase activity restricts HIV replication. PCIF1 inhibits HIV infection by enhancing stability of the transcription factor ETS1, which binds the HIV promoter to regulate viral transcription.","method":"Co-immunoprecipitation, PCIF1-depleted T cells, m6Am-seq, ubiquitination assay, viral replication assays, ETS1 stability analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, m6Am-seq, functional KD with mechanistic follow-up on downstream target, multiple orthogonal methods","pmids":["34545078"],"is_preprint":false},{"year":2022,"finding":"PCIF1 preferentially binds 2'-O-methylated Am over unmodified A due to increased binding affinity (KM ~0.4 μM for uncapped 5'-Am vs ~0.3 μM for cap analog). PCIF1 can methylate uncapped 5'-Am oligonucleotides with only ~5-6 fold lower activity than capped substrates. PCIF1 has ancillary methylation activity on internal adenosines (A and Am) with much lower efficiency. PCIF1 activity order: cap-Am > uncapped 5'-Am >> internal A/Am.","method":"In vitro binding and methyltransfer assays with defined substrates, kinetic analysis (KM measurements)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro reconstitution with kinetic parameters, multiple substrate comparisons in one study","pmids":["35189146"],"is_preprint":false},{"year":2022,"finding":"PCIF1 has significant methylation activity on single-stranded DNA deoxyadenosine, double-stranded RNA/DNA hybrids, and double-stranded DNA, though with lower catalytic efficiency than on its preferred RNA substrate. Activity order: ssRNA > RNA/DNA hybrid > ssDNA > dsDNA.","method":"In vitro enzymatic characterization with defined DNA and hybrid substrates","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with defined substrates, single lab but multiple substrate types tested","pmids":["35605980"],"is_preprint":false},{"year":2022,"finding":"CRISPR/Cas9-mediated depletion of PCIF1 in human colorectal cancer (CRC) cells leads to loss of cell migration, invasion, and colony formation. PCIF1 stabilizes FOS mRNA via m6Am modification; FOS in turn drives TGF-β regulation and tumor growth. During anti-PD-1 immunotherapy, the PCIF1-STAT1/IFITM3-IFN-γ axis also contributes to resistance.","method":"CRISPR/Cas9 KO, xenograft mouse models, m6Am-seq, mRNA stability assays, immunocompetent mouse tumor models, anti-PD-1 treatment","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with in vivo models, m6Am-seq identifying direct targets, and mechanistic follow-up on downstream targets","pmids":["36514940"],"is_preprint":false},{"year":2022,"finding":"PCIF1 is the m6Am methyltransferase responsible for m6Am modification in gastric cancer; PCIF1 modifies TM9SF1 mRNA with m6Am leading to decreased TM9SF1 translation. TM9SF1 reverses the effects of PCIF1 on gastric cancer cell aggressiveness.","method":"m6Am-seq analysis, PCIF1 silencing, translation assays, mouse tumor models, rescue experiments with TM9SF1","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — m6Am-seq identifying direct target, epistasis rescue experiment, in vivo model, multiple orthogonal methods","pmids":["35597784"],"is_preprint":false},{"year":2023,"finding":"PCIF1 promotes SARS-CoV-2 infection by sustaining expression of coronavirus receptors ACE2 and TMPRSS2 via m6Am-dependent mRNA stabilization. In PCIF1-depleted cells, ACE2/TMPRSS2 expression and viral infection are rescued by wild-type but not catalytically inactive PCIF1.","method":"CRISPR/Cas9 genome editing, genome-wide m6Am-exo-seq, RNA-seq, catalytically inactive PCIF1 rescue, viral infection assays in primary lung epithelial cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CRISPR KO, m6Am-exo-seq, catalytic mutant rescue, multiple orthogonal methods in one study","pmids":["36689652"],"is_preprint":false},{"year":2023,"finding":"CTBP2 is a cofactor of PCIF1 that promotes m6Am deposition on mRNA. CTBP2 binds similar mRNAs as PCIF1 (CLIP-Seq). Knockout of CTBP2 reduces PCIF1 occupancy on TET2 mRNA; the PCIF1-CTBP2 complex negatively regulates TET2 mRNA translation.","method":"Co-immunoprecipitation identifying CTBP2 as PCIF1 cofactor, CLIP-Seq, m6Am-Seq at single-base resolution, CTBP2/PCIF1 KO, translation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, CLIP-Seq, m6Am-Seq, functional KO assays, multiple orthogonal methods","pmids":["37643007"],"is_preprint":false},{"year":2024,"finding":"PCIF1 acts as a negative regulator of ciliogenesis through its m6Am methyltransferase activity. PCIF1 regulates BICD2 protein levels by reducing the stability and translation efficiency of BICD2 mRNA via m6Am modification. Depletion of PCIF1 increases BICD2 levels and promotes ciliation; BICD2 knockdown reverses the ciliation phenotype of PCIF1-depleted cells.","method":"PCIF1 depletion in RPE-1 cells, quantitative proteomics, m6Am-seq, single-base resolution LC-MS of m6Am site, mRNA stability and translation assays, epistasis rescue experiments","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — proteomics identifying target, LC-MS confirmation of m6Am site, epistasis rescue, multiple orthogonal methods","pmids":["38526325"],"is_preprint":false},{"year":2024,"finding":"PCIF1 promotes renal cell carcinoma progression by enhancing translation of LPP3 mRNA via m6Am modification. LPP3 regulates phosphatidic acid metabolism, preventing its mitochondrial accumulation and facilitating mitochondrial fission. Depletion of PCIF1 sensitizes RCC to sunitinib.","method":"m6Am-Exo-Seq identifying LPP3 as target, translation assays, mitochondrial morphology analysis, in vivo tumor models, pharmacological sensitivity assays","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 / Strong — m6Am-Exo-Seq, translation assays, in vivo models, mechanistic pathway follow-up, multiple orthogonal methods","pmids":["39422663"],"is_preprint":false},{"year":2024,"finding":"PCIF1 loss attenuates periodontal inflammation. PCIF1 promotes macrophage phagocytosis and migration through m6Am modification of Csf1r (CSF1R) mRNA signaling.","method":"Whole-body and myeloid lineage-specific Pcif1 knockout mice, macrophage phagocytosis and migration assays, m6Am analysis of Csf1r","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO models with cellular functional assays, single lab","pmids":["39290151"],"is_preprint":false},{"year":2024,"finding":"PCIF1 regulates the stability of RAB23 and CNOT6 mRNAs in opposite directions through m6A/m6Am modification. PCIF1 suppression reduces m6A levels of RAB23 and CNOT6 mRNAs. Rescue experiments confirm that PCIF1's methyltransferase activity is required for these regulatory effects.","method":"siRNA knockdown, mRNA stability assays, MeRIP-qPCR, rescue with wild-type vs catalytically inactive PCIF1","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-qPCR, mRNA stability assays, catalytic mutant rescue; single lab","pmids":["39451207"],"is_preprint":false},{"year":2024,"finding":"A population of PCIF1 is localized to the cytoplasm (not exclusively nuclear). Upon oxidative stress, PCIF1 redistributes to stress granules and physically interacts with G3BP and other stress granule components. Overexpressing full-length PCIF1 inhibits stress granule formation, while PCIF1 knockout slows stress granule disassembly. PCIF1 binds mRNAs in their coding sequences (not cap-proximal regions) as shown by eCLIP, and this binding increases upon oxidative stress. ChIP-Seq shows PCIF1 association with transcription start sites rather than gene bodies, indicating PCIF1's association with mature mRNA is not co-transcriptional.","method":"Cell fractionation, immunofluorescence, co-immunoprecipitation with G3BP and stress granule components, eCLIP, ChIP-Seq, PCIF1 overexpression and knockout","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (fractionation, IF, Co-IP, eCLIP, ChIP-Seq), single lab, preprint","pmids":["38766247"],"is_preprint":true},{"year":2025,"finding":"PCIF1 negatively regulates CD8+ T cell antitumor responses. PCIF1 KO elevates m6Am-modified ferroptosis suppressor gene transcripts (Fth1, Slc3a2) and the T cell activation gene Cd69, imparting resistance to ferroptosis and enhancing CD8+ T cell activation. Pcif1-deficient mice show enhanced responses to anti-PD-1 immunotherapy.","method":"Whole-body and T cell-specific Pcif1 KO mice, single-cell RNA-seq, proteomics, m6Am-sequencing, tumor growth assays, ferroptosis assays, CAR-T experiments","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO mice, proteomic and m6Am-seq mechanistic analyses, multiple orthogonal methods","pmids":["39762445"],"is_preprint":false},{"year":2025,"finding":"SERBP1 is a PCIF1 cofactor; the SERBP1-PCIF1 complex mediates m6Am deposition onto Maf1 mRNA in glutamatergic neurons. Increased PCIF1/SERBP1 adds m6Am to Maf1 mRNA, reduces MAF1 protein, and contributes to neuropathic pain and anxiety. Blocking SERBP1-PCIF1 upregulation abolishes m6Am gain on Maf1 and elevates MAF1.","method":"Co-immunoprecipitation (SERBP1-PCIF1 complex), m6Am-sequencing, conditional neuron-specific KO mice, AAV-mediated gene manipulation, behavioral pain assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP identifying novel cofactor, m6Am-seq confirming target, in vivo conditional KO and AAV rescue, multiple orthogonal methods","pmids":["40764612"],"is_preprint":false},{"year":2025,"finding":"The WW domain of PCIF1 is required for its inhibitory effect on glioma cell proliferation, independently of its methyltransferase activity. Forced nuclear expression of the WW domain reduces PCIF1 protein stability, diminishes PCIF1-RNA Pol II interaction, facilitates translocation of endogenous PCIF1 from nucleus to cytoplasm, and promotes PCIF1 degradation through the ubiquitin-proteasome system and autophagy-lysosomal pathway.","method":"Domain deletion/mutation analysis, overexpression of isolated WW domain, subcellular fractionation, Co-IP with RNA Pol II, proteasome/autophagy inhibitor assays, in vivo tumor models","journal":"NPJ precision oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mutagenesis, Co-IP, pharmacological pathway dissection; single lab","pmids":["41131141"],"is_preprint":false},{"year":2025,"finding":"PCIF1 drives oesophageal squamous cell carcinoma (OSCC) progression by suppressing MTF2 translation via m6Am modification of MTF2 mRNA. Knockdown of PCIF1 reduces OSCC progression; MTF2 knockdown counteracts this effect, confirming the PCIF1-MTF2 epistatic axis.","method":"PCIF1 KO/knockdown in vitro and in vivo, m6Am analysis of MTF2 mRNA, translation assays, epistasis rescue (MTF2 KD), anti-PD1 combination in mouse model","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO model, epistasis rescue, m6Am functional assays; single lab","pmids":["40156159"],"is_preprint":false},{"year":2026,"finding":"PCIF1 modulates glioblastoma cell migration and invasion by regulating INPP5B levels: PCIF1 knockdown upregulates INPP5B (a PI5-phosphatase), causing PI(3,4)P2 accumulation and enhanced AKT activation, promoting EMT and invasion. PCIF1 overexpression increases PI(3,4,5)P3 and promotes proteasomal degradation of AKT while increasing p-AKT levels.","method":"PCIF1 overexpression and knockdown, EMT marker analysis, phosphoinositide measurements, AKT/p-AKT western blotting, proteasome inhibitor assays, migration/invasion assays","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway dissection with phospholipid measurements and proteasome inhibition; single lab","pmids":["42145053"],"is_preprint":false},{"year":2026,"finding":"PCIF1 suppresses type I interferon induction in a methyltransferase-independent manner. PCIF1 attenuates IRF3 phosphorylation and nuclear translocation, suppressing IFNB1 transcription (increased nascent IFNB1 mRNA synthesis and promoter activity in PCIF1-deficient cells). Both wild-type PCIF1 and a methyltransferase-inactive mutant effectively suppress type I IFN induction.","method":"PCIF1 KO cells, poly(I:C) stimulation, IRF3 phosphorylation/nuclear translocation assays, nascent mRNA synthesis assay, promoter activity reporter, catalytically inactive PCIF1 rescue, STAT1 activation and ISG expression analysis","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic mutant rescue, IRF3 mechanistic assays, multiple orthogonal methods distinguishing methyltransferase-independent function","pmids":["41677666"],"is_preprint":false},{"year":2026,"finding":"GLI2 governs PCIF1 expression by binding the Pcif1 promoter. In the anterior cingulate cortex (ACC), PCIF1-mediated m6Am modification of Gap43 mRNA reduces GAP43 expression; loss of PCIF1 increases GAP43, leading to pre-LTP oversaturation and inflammatory pain/anxiety. Knockdown of GAP43 suppresses the pre-LTP oversaturation caused by PCIF1 reduction.","method":"Conditional Pcif1 KO in ACC neurons, m6Am-seq of Gap43 mRNA, chromatin immunoprecipitation (GLI2 on Pcif1 promoter), GAP43 knockdown epistasis, LTP recording, behavioral assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO, m6Am-seq, ChIP, epistasis rescue, electrophysiological readout, multiple orthogonal methods","pmids":["41712381"],"is_preprint":false},{"year":2026,"finding":"PCIF1-mediated m6Am modification is required for osteogenic differentiation of mesenchymal stem cells. Global or MSC-specific Pcif1 deletion causes osteoporosis in mice. PCIF1 stabilizes Wnt-related transcripts (Wnt11, Fzd4, Fgfr2) via m6Am modification; Pcif1 KO decreases their m6Am signals, accelerates mRNA degradation, downregulates active β-Catenin, and impairs osteogenesis. WNT agonist rescues the osteoporosis-like phenotype.","method":"Global and MSC-specific Pcif1 KO mice, m6Am-seq of Wnt-related mRNAs, mRNA stability assays, β-Catenin western blotting, WNT agonist rescue, bone phenotyping","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell type-specific KO mice, m6Am-seq, mRNA stability, pathway rescue with WNT agonist, multiple orthogonal methods","pmids":["41941537"],"is_preprint":false}],"current_model":"PCIF1 is a nuclear methyltransferase that uses its WW domain to bind Ser5-phosphorylated RNA Pol II CTD and co-transcriptionally deposits N6,2'-O-dimethyladenosine (m6Am) at the cap-proximal adenosine of nascent mRNAs; this modification can stabilize or destabilize specific target mRNAs and regulate their translation, thereby controlling diverse biological processes including β-cell survival (via PDX-1 ubiquitination/degradation), antiviral immunity (by modifying viral mRNA caps to dampen IFN-β responses), CD8+ T cell ferroptosis resistance and activation, ciliogenesis (via BICD2), osteogenesis (via Wnt pathway transcripts), and cancer cell invasion/proliferation; additionally, PCIF1 exerts methyltransferase-independent functions, including suppression of IRF3 activation to attenuate type I interferon responses and regulation of stress granule dynamics, while acting in complex with cofactors CTBP2 and SERBP1 for context-specific m6Am substrate targeting."},"narrative":{"mechanistic_narrative":"PCIF1 is a nuclear cap-specific RNA methyltransferase that co-transcriptionally deposits N6,2'-O-dimethyladenosine (m6Am) on the first transcribed nucleotide of capped mRNAs, thereby tuning transcript stability and translation across diverse cellular programs [PMID:32814042, PMID:33982754]. Its WW domain directly and preferentially binds the Ser5-phosphorylated (hyperphosphorylated) CTD of RNA polymerase II, recruiting the enzyme to transcription start sites of active genes in a manner strictly dependent on transcriptional activity and CTD phosphorylation, which positions it for cotranscriptional methylation of nascent mRNA caps [PMID:12565871, PMID:33982754]. Biochemically PCIF1 most efficiently methylates a 2'-O-methylated, capped 5' adenosine, with progressively lower activity on uncapped 5'-Am, internal adenosines, and DNA or hybrid substrates [PMID:35189146, PMID:35605980]. Through m6Am marking of specific targets PCIF1 either stabilizes transcripts (FOS, ACE2/TMPRSS2, LPP3, Wnt11/Fzd4/Fgfr2) or suppresses their translation/stability (TM9SF1, BICD2, MTF2, Maf1, Gap43), thereby controlling cancer cell invasion and proliferation, viral infection, ciliogenesis, osteogenic differentiation of mesenchymal stem cells, neuropathic pain, and CD8+ T cell ferroptosis resistance and antitumor activity [PMID:36514940, PMID:35597784, PMID:36689652, PMID:38526325, PMID:39422663, PMID:39762445, PMID:40764612, PMID:41712381, PMID:41941537]. Target selection is shaped by interchangeable cofactors: CTBP2 and SERBP1 each form complexes with PCIF1 to direct m6Am deposition onto context-specific substrates such as TET2 and Maf1 mRNA [PMID:37643007, PMID:40764612]. PCIF1 also executes methyltransferase-independent activities, suppressing type I interferon induction by attenuating IRF3 phosphorylation and nuclear translocation, and acting through its WW domain to restrain glioma cell proliferation [PMID:41677666, PMID:41131141]. In addition to its earliest-characterized role as SPOP/PCIF1 targeting the transcription factor PDX-1 for ubiquitination and proteasomal degradation to modulate β-cell survival, a cytoplasmic pool of PCIF1 redistributes to stress granules and modulates their dynamics [PMID:20811152, PMID:38766247].","teleology":[{"year":2003,"claim":"Established the molecular handle by which PCIF1 engages the transcription machinery, showing its WW domain selectively reads the phosphorylated Pol II CTD.","evidence":"CTD probe library screening, in vitro binding, Co-IP and immunofluorescence in HeLa cells","pmids":["12565871"],"confidence":"High","gaps":["Did not define an enzymatic activity for PCIF1","Functional consequence of CTD binding unknown at this stage"]},{"year":2004,"claim":"Identified PCIF1 (SPOP) as a nuclear inhibitor of the β-cell transcription factor PDX-1, the first specific functional partner.","evidence":"Yeast two-hybrid, Co-IP, reporter assays and immunofluorescence in MIN6 cells","pmids":["15121856"],"confidence":"High","gaps":["Mechanism of inhibition not resolved","Did not connect PDX-1 regulation to any catalytic or RNA-related activity"]},{"year":2006,"claim":"Mapped the TRAF and POZ domains as the PDX-1 interaction module and linked a diabetes-associated PDX-1 mutation to loss of PCIF1 regulation, establishing physiological relevance.","evidence":"Endogenous Co-IP, domain deletion/mutagenesis and reporter assays in MIN6 cells","pmids":["17126328"],"confidence":"High","gaps":["Inhibitory mechanism shown distinct from classical POZ corepressor recruitment but not otherwise defined"]},{"year":2009,"claim":"Showed PCIF1 negatively modulates Pol II transcriptional activity in vivo and relates to Pin1 in CTD regulation, reinforcing a transcription-linked function.","evidence":"PCIF1-knockout DT40 cells, reconstitution and transcriptional reporter assays","pmids":["19682092"],"confidence":"Medium","gaps":["Mechanism of transcriptional repression unresolved","Single lab; no biochemical activity assigned"]},{"year":2010,"claim":"Demonstrated PCIF1 targets PDX-1 for ubiquitination and proteasomal degradation in vivo, defining a concrete biological output controlling β-cell mass and glucose homeostasis.","evidence":"siRNA knockdown, heterozygous mouse genetics, ubiquitination and protein stability assays, glucose tolerance tests","pmids":["20811152"],"confidence":"High","gaps":["Relationship of this E3-adaptor-like activity to PCIF1's later-defined methyltransferase function unresolved"]},{"year":2020,"claim":"Defined PCIF1 as the mammalian cap-specific m6Am methyltransferase, reframing it as an RNA-modifying enzyme and linking m6Am to transcript stability.","evidence":"Pcif1 knockout mice, transcriptome analysis, in vitro methyltransferase assays, cross-species functional comparison","pmids":["32814042","30679132"],"confidence":"High","gaps":["How m6Am mechanistically alters individual transcript fate not yet resolved","Catalytic-dead Drosophila ortholog implies methylation-independent roles not yet explored"]},{"year":2021,"claim":"Localized PCIF1-dependent methylation to nascent mRNA by showing recruitment to active transcription start sites entirely dependent on Ser5-CTD phosphorylation, unifying the CTD-binding and methyltransferase activities into a cotranscriptional model.","evidence":"ChIP, subcellular fractionation, immunofluorescence and transcription-inhibition experiments in HeLa cells","pmids":["33982754"],"confidence":"High","gaps":["Did not address determinants of substrate-specific methylation outcomes"]},{"year":2021,"claim":"Connected PCIF1 m6Am activity to antiviral and immune outcomes, showing it modifies viral mRNA caps to dampen IFN-β responses and restricts HIV via ETS1 stabilization, with Vpr-driven PCIF1 degradation as a viral counter-strategy.","evidence":"Cell-based antiviral assays, in vitro methyltransferase assays, PCIF1 KO and catalytic mutants, m6Am-seq, Co-IP","pmids":["34266951","34545078"],"confidence":"High","gaps":["Opposing pro- and anti-viral roles across viruses not mechanistically reconciled","Selectivity of viral vs host cap modification undefined"]},{"year":2022,"claim":"Quantified PCIF1's substrate hierarchy, establishing cap-Am as the preferred substrate while documenting measurable activity on uncapped RNA, internal adenosines, and DNA/hybrid substrates.","evidence":"In vitro kinetic and methyltransfer assays with defined RNA, DNA and hybrid substrates","pmids":["35189146","35605980"],"confidence":"High","gaps":["Physiological relevance of ancillary internal-A and DNA methylation activities unestablished"]},{"year":2022,"claim":"Showed PCIF1 m6Am drives cancer cell aggressiveness through specific mRNA targets, stabilizing FOS in colorectal cancer and suppressing TM9SF1 translation in gastric cancer.","evidence":"CRISPR/Cas9 KO, m6Am-seq, mRNA stability and translation assays, xenograft and immunocompetent tumor models, anti-PD-1 treatment","pmids":["36514940","35597784"],"confidence":"High","gaps":["Why some m6Am targets are stabilized and others translationally repressed not explained","Determinants of target selection across tissues unknown"]},{"year":2023,"claim":"Identified CTBP2 as the first PCIF1 cofactor directing m6Am deposition and promoter SARS-CoV-2 entry-factor mRNA stabilization, advancing both the cofactor concept and infection biology.","evidence":"Co-IP, CLIP-Seq, m6Am-seq, KO and translation assays; m6Am-exo-seq and catalytic-mutant rescue in lung epithelial cells","pmids":["37643007","36689652"],"confidence":"High","gaps":["How cofactors reprogram substrate specificity mechanistically unresolved","Whether additional cofactors exist not yet known at this stage"]},{"year":2024,"claim":"Expanded the m6Am target landscape into ciliogenesis, renal cancer metabolism, macrophage immunity, and bidirectional transcript regulation, demonstrating broad context-specific control.","evidence":"PCIF1 depletion with proteomics, m6Am-seq/exo-seq, LC-MS site mapping, mRNA stability/translation assays, conditional KO mice, MeRIP-qPCR","pmids":["38526325","39422663","39290151","39451207"],"confidence":"High","gaps":["Mechanistic basis for opposite-direction regulation of RAB23 vs CNOT6 unexplained","Whether m6A vs m6Am marks are distinguished in some targets unclear"]},{"year":2024,"claim":"Revealed a cytoplasmic, non-cotranscriptional pool of PCIF1 that localizes to stress granules and binds mRNA coding sequences, broadening its functional repertoire beyond cap methylation.","evidence":"Fractionation, immunofluorescence, Co-IP with G3BP, eCLIP, ChIP-Seq, overexpression and KO (preprint)","pmids":["38766247"],"confidence":"Medium","gaps":["Preprint; awaits peer review","Catalytic dependence of stress granule role undefined","Functional consequence of CDS binding unknown"]},{"year":2025,"claim":"Established PCIF1 as a negative regulator of CD8+ T cell antitumor responses and identified SERBP1 as a second cofactor, linking m6Am control to immunotherapy efficacy and neural signaling.","evidence":"Conditional KO mice, scRNA-seq, proteomics, m6Am-seq, ferroptosis and CAR-T assays; Co-IP, AAV manipulation and behavioral assays","pmids":["39762445","40764612"],"confidence":"High","gaps":["How distinct cofactors are selected in different cell types unknown","Whether SERBP1 and CTBP2 complexes are mutually exclusive unresolved"]},{"year":2025,"claim":"Defined methyltransferase-independent PCIF1 functions, showing the WW domain restrains glioma proliferation and modulates PCIF1 stability/localization independent of catalysis.","evidence":"Domain mutagenesis, isolated WW domain expression, Co-IP with Pol II, proteasome/autophagy inhibitor assays, tumor models","pmids":["41131141"],"confidence":"Medium","gaps":["Single lab","Mechanism by which WW domain controls PCIF1 degradation incompletely defined"]},{"year":2026,"claim":"Consolidated PCIF1's role across interferon signaling, neural plasticity, osteogenesis and cancer, including a methyltransferase-independent suppression of IRF3/type I IFN and upstream transcriptional control of PCIF1 by GLI2.","evidence":"PCIF1 KO with poly(I:C), IRF3 assays and catalytic-mutant rescue; conditional KO mice, m6Am-seq, ChIP, electrophysiology, MSC-specific KO with WNT agonist rescue; phosphoinositide and AKT analyses","pmids":["41677666","41712381","41941537","42145053"],"confidence":"High","gaps":["How catalytic vs non-catalytic functions are partitioned in vivo unresolved","Integration of transcriptional (GLI2) and post-transcriptional (m6Am) layers incompletely mapped"]},{"year":null,"claim":"How PCIF1 reconciles its multiple molecular activities — cap m6Am methyltransferase, methyltransferase-independent IRF3/IFN suppressor, WW-domain growth regulator, and the early SPOP/PDX-1 ubiquitination-adaptor role — within a single coherent regulatory logic remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating cofactor binding with substrate selection","Relationship between the SPOP/ubiquitination function and RNA methyltransferase function unexplained","Rules governing transcript stabilization vs destabilization by m6Am undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[5,6,7,10,11]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[6,10,11]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[10,20]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2,8]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[6,8,12,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,9,14,21,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,13,17,24,25]}],"complexes":["PCIF1-CTBP2 complex","PCIF1-SERBP1 complex"],"partners":["RNA POL II (POLR2A CTD)","PDX-1","CTBP2","SERBP1","G3BP","VPR (HIV)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H4Z3","full_name":"mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase","aliases":["Cap-specific adenosine methyltransferase","CAPAM","hCAPAM","Phosphorylated CTD-interacting factor 1","hPCIF1","Protein phosphatase 1 regulatory subunit 121"],"length_aa":704,"mass_kda":80.7,"function":"Cap-specific adenosine methyltransferase that catalyzes formation of N(6),2'-O-dimethyladenosine cap (m6A(m)) by methylating the adenosine at the second transcribed position of capped mRNAs (PubMed:30467178, PubMed:30487554, PubMed:31279658, PubMed:31279659, PubMed:33428944). Recruited to the early elongation complex of RNA polymerase II (RNAPII) via interaction with POLR2A and mediates formation of m6A(m) co-transcriptionally (PubMed:30467178)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9H4Z3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PCIF1","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PCIF1","total_profiled":1310},"omim":[{"mim_id":"618626","title":"PHOSPHORYLATED C-TERMINAL DOMAIN-INTERACTING FACTOR 1; PCIF1","url":"https://www.omim.org/entry/618626"},{"mim_id":"602650","title":"SPECKLE-TYPE BTB/POZ PROTEIN; SPOP","url":"https://www.omim.org/entry/602650"},{"mim_id":"600733","title":"PANCREAS/DUODENUM HOMEOBOX PROTEIN 1; PDX1","url":"https://www.omim.org/entry/600733"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PCIF1"},"hgnc":{"alias_symbol":["bA465L10.1","PPP1R121","CAPAM","MT-A70"],"prev_symbol":["C20orf67"]},"alphafold":{"accession":"Q9H4Z3","domains":[{"cath_id":"2.20.70.10","chopping":"41-75","consensus_level":"high","plddt":82.136,"start":41,"end":75},{"cath_id":"-","chopping":"161-193_396-671","consensus_level":"medium","plddt":93.1311,"start":161,"end":671},{"cath_id":"-","chopping":"198-385","consensus_level":"high","plddt":95.5633,"start":198,"end":385}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4Z3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4Z3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H4Z3-F1-predicted_aligned_error_v6.png","plddt_mean":80.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PCIF1","jax_strain_url":"https://www.jax.org/strain/search?query=PCIF1"},"sequence":{"accession":"Q9H4Z3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H4Z3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H4Z3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H4Z3"}},"corpus_meta":[{"pmid":"20811152","id":"PMC_20811152","title":"Pcif1 modulates Pdx1 protein stability and pancreatic β cell function and survival in mice.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20811152","citation_count":78,"is_preprint":false},{"pmid":"32814042","id":"PMC_32814042","title":"The Mammalian Cap-Specific m6Am RNA Methyltransferase PCIF1 Regulates Transcript Levels in Mouse Tissues.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32814042","citation_count":67,"is_preprint":false},{"pmid":"15121856","id":"PMC_15121856","title":"Identification of PCIF1, a POZ domain protein that inhibits PDX-1 (MODY4) transcriptional activity.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15121856","citation_count":53,"is_preprint":false},{"pmid":"34545078","id":"PMC_34545078","title":"HIV reprograms host m6Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34545078","citation_count":52,"is_preprint":false},{"pmid":"12565871","id":"PMC_12565871","title":"PCIF1, a novel human WW domain-containing protein, interacts with the phosphorylated RNA polymerase II.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12565871","citation_count":52,"is_preprint":false},{"pmid":"36514940","id":"PMC_36514940","title":"Role of PCIF1-mediated 5'-cap N6-methyladeonsine mRNA methylation in colorectal cancer and anti-PD-1 immunotherapy.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/36514940","citation_count":50,"is_preprint":false},{"pmid":"35597784","id":"PMC_35597784","title":"m6Am methyltransferase PCIF1 is essential for aggressiveness of gastric cancer cells by inhibiting TM9SF1 mRNA translation.","date":"2022","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35597784","citation_count":49,"is_preprint":false},{"pmid":"36689652","id":"PMC_36689652","title":"PCIF1-mediated deposition of 5'-cap N6,2'-O-dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36689652","citation_count":34,"is_preprint":false},{"pmid":"34266951","id":"PMC_34266951","title":"Methylation of viral mRNA cap structures by PCIF1 attenuates the antiviral activity of interferon-β.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34266951","citation_count":34,"is_preprint":false},{"pmid":"32169278","id":"PMC_32169278","title":"A novel circular RNA, circ-ATAD1, contributes to gastric cancer cell progression by targeting miR-140-3p/YY1/PCIF1 signaling axis.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32169278","citation_count":27,"is_preprint":false},{"pmid":"37643007","id":"PMC_37643007","title":"The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/37643007","citation_count":25,"is_preprint":false},{"pmid":"39762445","id":"PMC_39762445","title":"The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity.","date":"2025","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39762445","citation_count":23,"is_preprint":false},{"pmid":"30679132","id":"PMC_30679132","title":"CAPAM: The mRNA Cap Adenosine N6-Methyltransferase.","date":"2019","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30679132","citation_count":21,"is_preprint":false},{"pmid":"17126328","id":"PMC_17126328","title":"Two conserved domains in PCIF1 mediate interaction with pancreatic transcription factor PDX-1.","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17126328","citation_count":21,"is_preprint":false},{"pmid":"35868483","id":"PMC_35868483","title":"Effects of the m6Am methyltransferase PCIF1 on cell proliferation and survival in gliomas.","date":"2022","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35868483","citation_count":17,"is_preprint":false},{"pmid":"33982754","id":"PMC_33982754","title":"The cap-specific m6A methyltransferase, PCIF1/CAPAM, is dynamically recruited to the gene promoter in a transcription-dependent manner.","date":"2021","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33982754","citation_count":16,"is_preprint":false},{"pmid":"35189146","id":"PMC_35189146","title":"Enzymatic characterization of mRNA cap adenosine-N6 methyltransferase PCIF1 activity on uncapped RNAs.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35189146","citation_count":15,"is_preprint":false},{"pmid":"34888238","id":"PMC_34888238","title":"A Pan-Cancer Analysis of the Oncogenic and Immunogenic Role of m6Am Methyltransferase PCIF1.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34888238","citation_count":15,"is_preprint":false},{"pmid":"37779183","id":"PMC_37779183","title":"PCIF1, the only methyltransferase of N6,2-O-dimethyladenosine.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37779183","citation_count":14,"is_preprint":false},{"pmid":"39422663","id":"PMC_39422663","title":"m6Am Methyltransferase PCIF1 Promotes LPP3 Mediated Phosphatidic Acid Metabolism and Renal Cell Carcinoma Progression.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39422663","citation_count":13,"is_preprint":false},{"pmid":"36282111","id":"PMC_36282111","title":"CAPturAM, a Chemo-Enzymatic Strategy for Selective Enrichment and Detection of Physiological CAPAM-Targets.","date":"2022","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/36282111","citation_count":12,"is_preprint":false},{"pmid":"35605980","id":"PMC_35605980","title":"Enzymatic Characterization of In Vitro Activity of RNA Methyltransferase PCIF1 on DNA.","date":"2022","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35605980","citation_count":11,"is_preprint":false},{"pmid":"38526325","id":"PMC_38526325","title":"m6Am methyltransferase PCIF1 negatively regulates ciliation by inhibiting BICD2 expression.","date":"2024","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38526325","citation_count":8,"is_preprint":false},{"pmid":"19682092","id":"PMC_19682092","title":"Prolyl isomerase Pin1 shares functional similarity with phosphorylated CTD interacting factor PCIF1 in vertebrate cells.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19682092","citation_count":6,"is_preprint":false},{"pmid":"39290151","id":"PMC_39290151","title":"m6Am Methyltransferase PCIF1 Regulates Periodontal Inflammation.","date":"2024","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/39290151","citation_count":4,"is_preprint":false},{"pmid":"40764612","id":"PMC_40764612","title":"SERBP1-PCIF1 complex-controlled m6Am modification in glutamatergic neurons of the primary somatosensory cortex is required for neuropathic pain in mice.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40764612","citation_count":3,"is_preprint":false},{"pmid":"39451207","id":"PMC_39451207","title":"Cap-Specific m6Am Methyltransferase PCIF1/CAPAM Regulates mRNA Stability of RAB23 and CNOT6 through the m6A Methyltransferase Activity.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/39451207","citation_count":2,"is_preprint":false},{"pmid":"39524541","id":"PMC_39524541","title":"Cap-specific terminal N6-methyladeonsine methylation of RNA mediated by PCIF1 and possible therapeutic implications.","date":"2023","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39524541","citation_count":2,"is_preprint":false},{"pmid":"41131141","id":"PMC_41131141","title":"The WW domain presents a promising target for the development of PCIF1 agonists in the treatment of glioma.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41131141","citation_count":2,"is_preprint":false},{"pmid":"40156159","id":"PMC_40156159","title":"PCIF1 drives oesophageal squamous cell carcinoma progression via m6Am-mediated suppression of MTF2 translation.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40156159","citation_count":1,"is_preprint":false},{"pmid":"39074568","id":"PMC_39074568","title":"LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression.","date":"2024","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/39074568","citation_count":1,"is_preprint":false},{"pmid":"40176045","id":"PMC_40176045","title":"Introduction of human m6Am methyltransferase PCIF1 facilitates the biosynthesis of terpenoids in Saccharomyces cerevisiae.","date":"2025","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/40176045","citation_count":1,"is_preprint":false},{"pmid":"42145053","id":"PMC_42145053","title":"PCIF1 modulates glioblastoma cell migration and invasion by altering PI(3,4)P2 levels through the PI5-phosphatase INPP5B.","date":"2026","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/42145053","citation_count":0,"is_preprint":false},{"pmid":"38766247","id":"PMC_38766247","title":"PCIF1 is partly cytoplasmic, dynamically localizes to stress granules and binds mRNA coding regions upon oxidative stress.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38766247","citation_count":0,"is_preprint":false},{"pmid":"41677666","id":"PMC_41677666","title":"PCIF1 Attenuates Type I Interferon Induction by Inhibiting IRF3 Activation in a Methyltransferase-Independent Manner.","date":"2026","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41677666","citation_count":0,"is_preprint":false},{"pmid":"41712381","id":"PMC_41712381","title":"PCIF1-mediated m6Am modification in ACC neurons participates in inflammatory pain and anxiety.","date":"2026","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41712381","citation_count":0,"is_preprint":false},{"pmid":"41941537","id":"PMC_41941537","title":"The m6Am methyltransferase PCIF1 promotes osteogenic differentiation of mesenchymal stem cells through stabilization of Wnt-related transcripts.","date":"2026","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/41941537","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19033,"output_tokens":7779,"usd":0.086892,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17321,"output_tokens":5551,"usd":0.11269,"stage2_stop_reason":"end_turn"},"total_usd":0.199582,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"PCIF1 contains a WW domain that directly and preferentially binds to the phosphorylated (hyperphosphorylated) CTD of RNA polymerase II (RNAP IIO) compared to unphosphorylated CTD, both in vitro and in vivo. PCIF1 and endogenous RNAP IIO co-localize in the cell nucleus.\",\n      \"method\": \"32P-labeled CTD probe screening of cDNA library, in vitro binding assay, co-immunoprecipitation, double immunofluorescence in HeLa cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal in vitro and in vivo binding assays with co-localization, replicated across multiple methods in the same study\",\n      \"pmids\": [\"12565871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PCIF1 (also called SPOP) interacts with the C-terminus of PDX-1 both in vitro and in vivo, localizes to the nucleus in a speckled pattern, and inhibits PDX-1 transactivation of target gene promoters in a dose-dependent manner requiring critical amino acids in the PDX-1 C-terminus.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid, reporter gene assays, immunofluorescence, overexpression in MIN6 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pulldown, Co-IP, reporter assay, localization) in a single rigorous study\",\n      \"pmids\": [\"15121856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Within PCIF1, both the TRAF and POZ domains are required for physical and functional interaction with the C-terminus of PDX-1; the C-terminal domain of PCIF1 directs its nuclear localization. The human PDX-1 diabetes-associated mutation E224K disrupts PCIF1-mediated inhibition of PDX-1 transactivation. Inhibition occurs by a mechanism distinct from classical POZ domain recruitment of co-repressors/HDACs.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins in MIN6 cells, domain deletion/mutation analysis, reporter gene assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — endogenous Co-IP plus domain mutagenesis and functional reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"17126328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PCIF1 negatively modulates RNA Pol II activity in vivo. In PCIF1-deficient chicken DT40 cells, Pin1 (a prolyl isomerase with overlapping CTD-binding specificity) is significantly upregulated. PCIF1 and Pin1 share overlapping subcellular localization and similar inhibitory effects on transcriptional activation by Pol II.\",\n      \"method\": \"PCIF1-knockout DT40 cell lines, reconstitution experiments, transcriptional reporter assays, subcellular localization studies\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with functional readout and reconstitution, single lab\",\n      \"pmids\": [\"19682092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PCIF1 (SPOP) targets PDX-1 for ubiquitination and proteasomal degradation. Silencing of Pcif1 increases Pdx1 protein levels in cultured mouse β cells. Pcif1 heterozygosity normalizes Pdx1 protein levels in Pdx1+/- islets, improves glucose homeostasis, β cell function, and normalizes β cell mass by modulating β cell survival.\",\n      \"method\": \"siRNA knockdown, heterozygous mouse genetics, protein stability assays, ubiquitination assays, glucose tolerance tests, β cell mass measurements\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model plus in vitro ubiquitination assay, multiple orthogonal methods across cell and animal models\",\n      \"pmids\": [\"20811152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PCIF1 (also called CAPAM) is a mRNA cap adenosine N6-methyltransferase that methylates adenosine when it is the first transcribed nucleotide of capped mRNAs.\",\n      \"method\": \"Review/summary citing identification of enzymatic activity (references original biochemical characterization studies)\",\n      \"journal\": \"Trends in biochemical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Strong — review summarizing biochemical identification; mechanistic detail confirmed by multiple primary studies below\",\n      \"pmids\": [\"30679132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PCIF1 is the mammalian cap-specific m6Am RNA methyltransferase responsible for N6-methylation of 2'-O-methyladenosine at the first transcribed position. Loss of PCIF1 in mice does not affect viability or fertility but reduces body weight. Transcriptome analyses support a role for cap-specific m6Am in stabilizing transcripts. Drosophila Pcif1 is catalytically dead but retains Ser5-phosphorylated CTD binding. Trypanosoma Pcif1 is an m6Am methylase contributing to hypermethylated cap4.\",\n      \"method\": \"Pcif1 knockout mice, transcriptome analysis, biochemical methyltransferase assay, phylogenetic/functional comparison across species\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo KO mouse model combined with transcriptomics and biochemical activity assays, multiple orthogonal methods\",\n      \"pmids\": [\"32814042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PCIF1 efficiently modifies VSV mRNA cap structures to m7Gpppm6Am and attenuates the antiviral effects of interferon-β. PCIF1-dependent modification of VSV mRNA caps does not affect mRNA stability, translation, or viral infectivity, but specifically reduces the antiviral response. Cells lacking PCIF1 or expressing catalytically inactive PCIF1 show augmented inhibition of viral replication after IFN-β treatment. PCIF1 also modifies mRNA caps of rabies and measles viruses.\",\n      \"method\": \"Cell-based antiviral assays, in vitro biochemical methyltransferase assays, PCIF1 knockout cells, catalytically inactive PCIF1 mutant, mRNA stability/translation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution plus cell-based assays with catalytic mutant, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"34266951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PCIF1 is recruited to promoters of a broad range of Pol II-transcribed genes, predominantly at transcription start sites, in a manner entirely dependent on transcriptional activity and Ser5-phosphorylation of the CTD. PCIF1 is mainly localized to transcriptionally active chromatin, suggesting cotranscriptional N6-methylation of the first adenosine of nascent mRNAs.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence microscopy, chromatin immunoprecipitation (ChIP) in HeLa cells, transcription inhibition experiments\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, fractionation, and immunofluorescence with functional dependency experiments, multiple orthogonal methods\",\n      \"pmids\": [\"33982754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIV Vpr protein interacts with PCIF1 and induces PCIF1 ubiquitination and degradation, thereby reprogramming the host m6Am RNA methylome. PCIF1 methyltransferase activity restricts HIV replication. PCIF1 inhibits HIV infection by enhancing stability of the transcription factor ETS1, which binds the HIV promoter to regulate viral transcription.\",\n      \"method\": \"Co-immunoprecipitation, PCIF1-depleted T cells, m6Am-seq, ubiquitination assay, viral replication assays, ETS1 stability analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, m6Am-seq, functional KD with mechanistic follow-up on downstream target, multiple orthogonal methods\",\n      \"pmids\": [\"34545078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PCIF1 preferentially binds 2'-O-methylated Am over unmodified A due to increased binding affinity (KM ~0.4 μM for uncapped 5'-Am vs ~0.3 μM for cap analog). PCIF1 can methylate uncapped 5'-Am oligonucleotides with only ~5-6 fold lower activity than capped substrates. PCIF1 has ancillary methylation activity on internal adenosines (A and Am) with much lower efficiency. PCIF1 activity order: cap-Am > uncapped 5'-Am >> internal A/Am.\",\n      \"method\": \"In vitro binding and methyltransfer assays with defined substrates, kinetic analysis (KM measurements)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro reconstitution with kinetic parameters, multiple substrate comparisons in one study\",\n      \"pmids\": [\"35189146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PCIF1 has significant methylation activity on single-stranded DNA deoxyadenosine, double-stranded RNA/DNA hybrids, and double-stranded DNA, though with lower catalytic efficiency than on its preferred RNA substrate. Activity order: ssRNA > RNA/DNA hybrid > ssDNA > dsDNA.\",\n      \"method\": \"In vitro enzymatic characterization with defined DNA and hybrid substrates\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with defined substrates, single lab but multiple substrate types tested\",\n      \"pmids\": [\"35605980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRISPR/Cas9-mediated depletion of PCIF1 in human colorectal cancer (CRC) cells leads to loss of cell migration, invasion, and colony formation. PCIF1 stabilizes FOS mRNA via m6Am modification; FOS in turn drives TGF-β regulation and tumor growth. During anti-PD-1 immunotherapy, the PCIF1-STAT1/IFITM3-IFN-γ axis also contributes to resistance.\",\n      \"method\": \"CRISPR/Cas9 KO, xenograft mouse models, m6Am-seq, mRNA stability assays, immunocompetent mouse tumor models, anti-PD-1 treatment\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with in vivo models, m6Am-seq identifying direct targets, and mechanistic follow-up on downstream targets\",\n      \"pmids\": [\"36514940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PCIF1 is the m6Am methyltransferase responsible for m6Am modification in gastric cancer; PCIF1 modifies TM9SF1 mRNA with m6Am leading to decreased TM9SF1 translation. TM9SF1 reverses the effects of PCIF1 on gastric cancer cell aggressiveness.\",\n      \"method\": \"m6Am-seq analysis, PCIF1 silencing, translation assays, mouse tumor models, rescue experiments with TM9SF1\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — m6Am-seq identifying direct target, epistasis rescue experiment, in vivo model, multiple orthogonal methods\",\n      \"pmids\": [\"35597784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PCIF1 promotes SARS-CoV-2 infection by sustaining expression of coronavirus receptors ACE2 and TMPRSS2 via m6Am-dependent mRNA stabilization. In PCIF1-depleted cells, ACE2/TMPRSS2 expression and viral infection are rescued by wild-type but not catalytically inactive PCIF1.\",\n      \"method\": \"CRISPR/Cas9 genome editing, genome-wide m6Am-exo-seq, RNA-seq, catalytically inactive PCIF1 rescue, viral infection assays in primary lung epithelial cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CRISPR KO, m6Am-exo-seq, catalytic mutant rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"36689652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CTBP2 is a cofactor of PCIF1 that promotes m6Am deposition on mRNA. CTBP2 binds similar mRNAs as PCIF1 (CLIP-Seq). Knockout of CTBP2 reduces PCIF1 occupancy on TET2 mRNA; the PCIF1-CTBP2 complex negatively regulates TET2 mRNA translation.\",\n      \"method\": \"Co-immunoprecipitation identifying CTBP2 as PCIF1 cofactor, CLIP-Seq, m6Am-Seq at single-base resolution, CTBP2/PCIF1 KO, translation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, CLIP-Seq, m6Am-Seq, functional KO assays, multiple orthogonal methods\",\n      \"pmids\": [\"37643007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCIF1 acts as a negative regulator of ciliogenesis through its m6Am methyltransferase activity. PCIF1 regulates BICD2 protein levels by reducing the stability and translation efficiency of BICD2 mRNA via m6Am modification. Depletion of PCIF1 increases BICD2 levels and promotes ciliation; BICD2 knockdown reverses the ciliation phenotype of PCIF1-depleted cells.\",\n      \"method\": \"PCIF1 depletion in RPE-1 cells, quantitative proteomics, m6Am-seq, single-base resolution LC-MS of m6Am site, mRNA stability and translation assays, epistasis rescue experiments\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — proteomics identifying target, LC-MS confirmation of m6Am site, epistasis rescue, multiple orthogonal methods\",\n      \"pmids\": [\"38526325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCIF1 promotes renal cell carcinoma progression by enhancing translation of LPP3 mRNA via m6Am modification. LPP3 regulates phosphatidic acid metabolism, preventing its mitochondrial accumulation and facilitating mitochondrial fission. Depletion of PCIF1 sensitizes RCC to sunitinib.\",\n      \"method\": \"m6Am-Exo-Seq identifying LPP3 as target, translation assays, mitochondrial morphology analysis, in vivo tumor models, pharmacological sensitivity assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — m6Am-Exo-Seq, translation assays, in vivo models, mechanistic pathway follow-up, multiple orthogonal methods\",\n      \"pmids\": [\"39422663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCIF1 loss attenuates periodontal inflammation. PCIF1 promotes macrophage phagocytosis and migration through m6Am modification of Csf1r (CSF1R) mRNA signaling.\",\n      \"method\": \"Whole-body and myeloid lineage-specific Pcif1 knockout mice, macrophage phagocytosis and migration assays, m6Am analysis of Csf1r\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO models with cellular functional assays, single lab\",\n      \"pmids\": [\"39290151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PCIF1 regulates the stability of RAB23 and CNOT6 mRNAs in opposite directions through m6A/m6Am modification. PCIF1 suppression reduces m6A levels of RAB23 and CNOT6 mRNAs. Rescue experiments confirm that PCIF1's methyltransferase activity is required for these regulatory effects.\",\n      \"method\": \"siRNA knockdown, mRNA stability assays, MeRIP-qPCR, rescue with wild-type vs catalytically inactive PCIF1\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-qPCR, mRNA stability assays, catalytic mutant rescue; single lab\",\n      \"pmids\": [\"39451207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A population of PCIF1 is localized to the cytoplasm (not exclusively nuclear). Upon oxidative stress, PCIF1 redistributes to stress granules and physically interacts with G3BP and other stress granule components. Overexpressing full-length PCIF1 inhibits stress granule formation, while PCIF1 knockout slows stress granule disassembly. PCIF1 binds mRNAs in their coding sequences (not cap-proximal regions) as shown by eCLIP, and this binding increases upon oxidative stress. ChIP-Seq shows PCIF1 association with transcription start sites rather than gene bodies, indicating PCIF1's association with mature mRNA is not co-transcriptional.\",\n      \"method\": \"Cell fractionation, immunofluorescence, co-immunoprecipitation with G3BP and stress granule components, eCLIP, ChIP-Seq, PCIF1 overexpression and knockout\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (fractionation, IF, Co-IP, eCLIP, ChIP-Seq), single lab, preprint\",\n      \"pmids\": [\"38766247\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PCIF1 negatively regulates CD8+ T cell antitumor responses. PCIF1 KO elevates m6Am-modified ferroptosis suppressor gene transcripts (Fth1, Slc3a2) and the T cell activation gene Cd69, imparting resistance to ferroptosis and enhancing CD8+ T cell activation. Pcif1-deficient mice show enhanced responses to anti-PD-1 immunotherapy.\",\n      \"method\": \"Whole-body and T cell-specific Pcif1 KO mice, single-cell RNA-seq, proteomics, m6Am-sequencing, tumor growth assays, ferroptosis assays, CAR-T experiments\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO mice, proteomic and m6Am-seq mechanistic analyses, multiple orthogonal methods\",\n      \"pmids\": [\"39762445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SERBP1 is a PCIF1 cofactor; the SERBP1-PCIF1 complex mediates m6Am deposition onto Maf1 mRNA in glutamatergic neurons. Increased PCIF1/SERBP1 adds m6Am to Maf1 mRNA, reduces MAF1 protein, and contributes to neuropathic pain and anxiety. Blocking SERBP1-PCIF1 upregulation abolishes m6Am gain on Maf1 and elevates MAF1.\",\n      \"method\": \"Co-immunoprecipitation (SERBP1-PCIF1 complex), m6Am-sequencing, conditional neuron-specific KO mice, AAV-mediated gene manipulation, behavioral pain assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP identifying novel cofactor, m6Am-seq confirming target, in vivo conditional KO and AAV rescue, multiple orthogonal methods\",\n      \"pmids\": [\"40764612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The WW domain of PCIF1 is required for its inhibitory effect on glioma cell proliferation, independently of its methyltransferase activity. Forced nuclear expression of the WW domain reduces PCIF1 protein stability, diminishes PCIF1-RNA Pol II interaction, facilitates translocation of endogenous PCIF1 from nucleus to cytoplasm, and promotes PCIF1 degradation through the ubiquitin-proteasome system and autophagy-lysosomal pathway.\",\n      \"method\": \"Domain deletion/mutation analysis, overexpression of isolated WW domain, subcellular fractionation, Co-IP with RNA Pol II, proteasome/autophagy inhibitor assays, in vivo tumor models\",\n      \"journal\": \"NPJ precision oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutagenesis, Co-IP, pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"41131141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PCIF1 drives oesophageal squamous cell carcinoma (OSCC) progression by suppressing MTF2 translation via m6Am modification of MTF2 mRNA. Knockdown of PCIF1 reduces OSCC progression; MTF2 knockdown counteracts this effect, confirming the PCIF1-MTF2 epistatic axis.\",\n      \"method\": \"PCIF1 KO/knockdown in vitro and in vivo, m6Am analysis of MTF2 mRNA, translation assays, epistasis rescue (MTF2 KD), anti-PD1 combination in mouse model\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO model, epistasis rescue, m6Am functional assays; single lab\",\n      \"pmids\": [\"40156159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PCIF1 modulates glioblastoma cell migration and invasion by regulating INPP5B levels: PCIF1 knockdown upregulates INPP5B (a PI5-phosphatase), causing PI(3,4)P2 accumulation and enhanced AKT activation, promoting EMT and invasion. PCIF1 overexpression increases PI(3,4,5)P3 and promotes proteasomal degradation of AKT while increasing p-AKT levels.\",\n      \"method\": \"PCIF1 overexpression and knockdown, EMT marker analysis, phosphoinositide measurements, AKT/p-AKT western blotting, proteasome inhibitor assays, migration/invasion assays\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway dissection with phospholipid measurements and proteasome inhibition; single lab\",\n      \"pmids\": [\"42145053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PCIF1 suppresses type I interferon induction in a methyltransferase-independent manner. PCIF1 attenuates IRF3 phosphorylation and nuclear translocation, suppressing IFNB1 transcription (increased nascent IFNB1 mRNA synthesis and promoter activity in PCIF1-deficient cells). Both wild-type PCIF1 and a methyltransferase-inactive mutant effectively suppress type I IFN induction.\",\n      \"method\": \"PCIF1 KO cells, poly(I:C) stimulation, IRF3 phosphorylation/nuclear translocation assays, nascent mRNA synthesis assay, promoter activity reporter, catalytically inactive PCIF1 rescue, STAT1 activation and ISG expression analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic mutant rescue, IRF3 mechanistic assays, multiple orthogonal methods distinguishing methyltransferase-independent function\",\n      \"pmids\": [\"41677666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GLI2 governs PCIF1 expression by binding the Pcif1 promoter. In the anterior cingulate cortex (ACC), PCIF1-mediated m6Am modification of Gap43 mRNA reduces GAP43 expression; loss of PCIF1 increases GAP43, leading to pre-LTP oversaturation and inflammatory pain/anxiety. Knockdown of GAP43 suppresses the pre-LTP oversaturation caused by PCIF1 reduction.\",\n      \"method\": \"Conditional Pcif1 KO in ACC neurons, m6Am-seq of Gap43 mRNA, chromatin immunoprecipitation (GLI2 on Pcif1 promoter), GAP43 knockdown epistasis, LTP recording, behavioral assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO, m6Am-seq, ChIP, epistasis rescue, electrophysiological readout, multiple orthogonal methods\",\n      \"pmids\": [\"41712381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"PCIF1-mediated m6Am modification is required for osteogenic differentiation of mesenchymal stem cells. Global or MSC-specific Pcif1 deletion causes osteoporosis in mice. PCIF1 stabilizes Wnt-related transcripts (Wnt11, Fzd4, Fgfr2) via m6Am modification; Pcif1 KO decreases their m6Am signals, accelerates mRNA degradation, downregulates active β-Catenin, and impairs osteogenesis. WNT agonist rescues the osteoporosis-like phenotype.\",\n      \"method\": \"Global and MSC-specific Pcif1 KO mice, m6Am-seq of Wnt-related mRNAs, mRNA stability assays, β-Catenin western blotting, WNT agonist rescue, bone phenotyping\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell type-specific KO mice, m6Am-seq, mRNA stability, pathway rescue with WNT agonist, multiple orthogonal methods\",\n      \"pmids\": [\"41941537\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PCIF1 is a nuclear methyltransferase that uses its WW domain to bind Ser5-phosphorylated RNA Pol II CTD and co-transcriptionally deposits N6,2'-O-dimethyladenosine (m6Am) at the cap-proximal adenosine of nascent mRNAs; this modification can stabilize or destabilize specific target mRNAs and regulate their translation, thereby controlling diverse biological processes including β-cell survival (via PDX-1 ubiquitination/degradation), antiviral immunity (by modifying viral mRNA caps to dampen IFN-β responses), CD8+ T cell ferroptosis resistance and activation, ciliogenesis (via BICD2), osteogenesis (via Wnt pathway transcripts), and cancer cell invasion/proliferation; additionally, PCIF1 exerts methyltransferase-independent functions, including suppression of IRF3 activation to attenuate type I interferon responses and regulation of stress granule dynamics, while acting in complex with cofactors CTBP2 and SERBP1 for context-specific m6Am substrate targeting.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PCIF1 is a nuclear cap-specific RNA methyltransferase that co-transcriptionally deposits N6,2'-O-dimethyladenosine (m6Am) on the first transcribed nucleotide of capped mRNAs, thereby tuning transcript stability and translation across diverse cellular programs [#6, #8]. Its WW domain directly and preferentially binds the Ser5-phosphorylated (hyperphosphorylated) CTD of RNA polymerase II, recruiting the enzyme to transcription start sites of active genes in a manner strictly dependent on transcriptional activity and CTD phosphorylation, which positions it for cotranscriptional methylation of nascent mRNA caps [#0, #8]. Biochemically PCIF1 most efficiently methylates a 2'-O-methylated, capped 5' adenosine, with progressively lower activity on uncapped 5'-Am, internal adenosines, and DNA or hybrid substrates [#10, #11]. Through m6Am marking of specific targets PCIF1 either stabilizes transcripts (FOS, ACE2/TMPRSS2, LPP3, Wnt11/Fzd4/Fgfr2) or suppresses their translation/stability (TM9SF1, BICD2, MTF2, Maf1, Gap43), thereby controlling cancer cell invasion and proliferation, viral infection, ciliogenesis, osteogenic differentiation of mesenchymal stem cells, neuropathic pain, and CD8+ T cell ferroptosis resistance and antitumor activity [#12, #13, #14, #16, #17, #21, #22, #27, #28]. Target selection is shaped by interchangeable cofactors: CTBP2 and SERBP1 each form complexes with PCIF1 to direct m6Am deposition onto context-specific substrates such as TET2 and Maf1 mRNA [#15, #22]. PCIF1 also executes methyltransferase-independent activities, suppressing type I interferon induction by attenuating IRF3 phosphorylation and nuclear translocation, and acting through its WW domain to restrain glioma cell proliferation [#26, #23]. In addition to its earliest-characterized role as SPOP/PCIF1 targeting the transcription factor PDX-1 for ubiquitination and proteasomal degradation to modulate β-cell survival, a cytoplasmic pool of PCIF1 redistributes to stress granules and modulates their dynamics [#4, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the molecular handle by which PCIF1 engages the transcription machinery, showing its WW domain selectively reads the phosphorylated Pol II CTD.\",\n      \"evidence\": \"CTD probe library screening, in vitro binding, Co-IP and immunofluorescence in HeLa cells\",\n      \"pmids\": [\"12565871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define an enzymatic activity for PCIF1\", \"Functional consequence of CTD binding unknown at this stage\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified PCIF1 (SPOP) as a nuclear inhibitor of the β-cell transcription factor PDX-1, the first specific functional partner.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, reporter assays and immunofluorescence in MIN6 cells\",\n      \"pmids\": [\"15121856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of inhibition not resolved\", \"Did not connect PDX-1 regulation to any catalytic or RNA-related activity\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped the TRAF and POZ domains as the PDX-1 interaction module and linked a diabetes-associated PDX-1 mutation to loss of PCIF1 regulation, establishing physiological relevance.\",\n      \"evidence\": \"Endogenous Co-IP, domain deletion/mutagenesis and reporter assays in MIN6 cells\",\n      \"pmids\": [\"17126328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitory mechanism shown distinct from classical POZ corepressor recruitment but not otherwise defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed PCIF1 negatively modulates Pol II transcriptional activity in vivo and relates to Pin1 in CTD regulation, reinforcing a transcription-linked function.\",\n      \"evidence\": \"PCIF1-knockout DT40 cells, reconstitution and transcriptional reporter assays\",\n      \"pmids\": [\"19682092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of transcriptional repression unresolved\", \"Single lab; no biochemical activity assigned\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated PCIF1 targets PDX-1 for ubiquitination and proteasomal degradation in vivo, defining a concrete biological output controlling β-cell mass and glucose homeostasis.\",\n      \"evidence\": \"siRNA knockdown, heterozygous mouse genetics, ubiquitination and protein stability assays, glucose tolerance tests\",\n      \"pmids\": [\"20811152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship of this E3-adaptor-like activity to PCIF1's later-defined methyltransferase function unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined PCIF1 as the mammalian cap-specific m6Am methyltransferase, reframing it as an RNA-modifying enzyme and linking m6Am to transcript stability.\",\n      \"evidence\": \"Pcif1 knockout mice, transcriptome analysis, in vitro methyltransferase assays, cross-species functional comparison\",\n      \"pmids\": [\"32814042\", \"30679132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How m6Am mechanistically alters individual transcript fate not yet resolved\", \"Catalytic-dead Drosophila ortholog implies methylation-independent roles not yet explored\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Localized PCIF1-dependent methylation to nascent mRNA by showing recruitment to active transcription start sites entirely dependent on Ser5-CTD phosphorylation, unifying the CTD-binding and methyltransferase activities into a cotranscriptional model.\",\n      \"evidence\": \"ChIP, subcellular fractionation, immunofluorescence and transcription-inhibition experiments in HeLa cells\",\n      \"pmids\": [\"33982754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address determinants of substrate-specific methylation outcomes\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected PCIF1 m6Am activity to antiviral and immune outcomes, showing it modifies viral mRNA caps to dampen IFN-β responses and restricts HIV via ETS1 stabilization, with Vpr-driven PCIF1 degradation as a viral counter-strategy.\",\n      \"evidence\": \"Cell-based antiviral assays, in vitro methyltransferase assays, PCIF1 KO and catalytic mutants, m6Am-seq, Co-IP\",\n      \"pmids\": [\"34266951\", \"34545078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Opposing pro- and anti-viral roles across viruses not mechanistically reconciled\", \"Selectivity of viral vs host cap modification undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Quantified PCIF1's substrate hierarchy, establishing cap-Am as the preferred substrate while documenting measurable activity on uncapped RNA, internal adenosines, and DNA/hybrid substrates.\",\n      \"evidence\": \"In vitro kinetic and methyltransfer assays with defined RNA, DNA and hybrid substrates\",\n      \"pmids\": [\"35189146\", \"35605980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of ancillary internal-A and DNA methylation activities unestablished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed PCIF1 m6Am drives cancer cell aggressiveness through specific mRNA targets, stabilizing FOS in colorectal cancer and suppressing TM9SF1 translation in gastric cancer.\",\n      \"evidence\": \"CRISPR/Cas9 KO, m6Am-seq, mRNA stability and translation assays, xenograft and immunocompetent tumor models, anti-PD-1 treatment\",\n      \"pmids\": [\"36514940\", \"35597784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why some m6Am targets are stabilized and others translationally repressed not explained\", \"Determinants of target selection across tissues unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified CTBP2 as the first PCIF1 cofactor directing m6Am deposition and promoter SARS-CoV-2 entry-factor mRNA stabilization, advancing both the cofactor concept and infection biology.\",\n      \"evidence\": \"Co-IP, CLIP-Seq, m6Am-seq, KO and translation assays; m6Am-exo-seq and catalytic-mutant rescue in lung epithelial cells\",\n      \"pmids\": [\"37643007\", \"36689652\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cofactors reprogram substrate specificity mechanistically unresolved\", \"Whether additional cofactors exist not yet known at this stage\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Expanded the m6Am target landscape into ciliogenesis, renal cancer metabolism, macrophage immunity, and bidirectional transcript regulation, demonstrating broad context-specific control.\",\n      \"evidence\": \"PCIF1 depletion with proteomics, m6Am-seq/exo-seq, LC-MS site mapping, mRNA stability/translation assays, conditional KO mice, MeRIP-qPCR\",\n      \"pmids\": [\"38526325\", \"39422663\", \"39290151\", \"39451207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis for opposite-direction regulation of RAB23 vs CNOT6 unexplained\", \"Whether m6A vs m6Am marks are distinguished in some targets unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a cytoplasmic, non-cotranscriptional pool of PCIF1 that localizes to stress granules and binds mRNA coding sequences, broadening its functional repertoire beyond cap methylation.\",\n      \"evidence\": \"Fractionation, immunofluorescence, Co-IP with G3BP, eCLIP, ChIP-Seq, overexpression and KO (preprint)\",\n      \"pmids\": [\"38766247\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint; awaits peer review\", \"Catalytic dependence of stress granule role undefined\", \"Functional consequence of CDS binding unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established PCIF1 as a negative regulator of CD8+ T cell antitumor responses and identified SERBP1 as a second cofactor, linking m6Am control to immunotherapy efficacy and neural signaling.\",\n      \"evidence\": \"Conditional KO mice, scRNA-seq, proteomics, m6Am-seq, ferroptosis and CAR-T assays; Co-IP, AAV manipulation and behavioral assays\",\n      \"pmids\": [\"39762445\", \"40764612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How distinct cofactors are selected in different cell types unknown\", \"Whether SERBP1 and CTBP2 complexes are mutually exclusive unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined methyltransferase-independent PCIF1 functions, showing the WW domain restrains glioma proliferation and modulates PCIF1 stability/localization independent of catalysis.\",\n      \"evidence\": \"Domain mutagenesis, isolated WW domain expression, Co-IP with Pol II, proteasome/autophagy inhibitor assays, tumor models\",\n      \"pmids\": [\"41131141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Mechanism by which WW domain controls PCIF1 degradation incompletely defined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Consolidated PCIF1's role across interferon signaling, neural plasticity, osteogenesis and cancer, including a methyltransferase-independent suppression of IRF3/type I IFN and upstream transcriptional control of PCIF1 by GLI2.\",\n      \"evidence\": \"PCIF1 KO with poly(I:C), IRF3 assays and catalytic-mutant rescue; conditional KO mice, m6Am-seq, ChIP, electrophysiology, MSC-specific KO with WNT agonist rescue; phosphoinositide and AKT analyses\",\n      \"pmids\": [\"41677666\", \"41712381\", \"41941537\", \"42145053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How catalytic vs non-catalytic functions are partitioned in vivo unresolved\", \"Integration of transcriptional (GLI2) and post-transcriptional (m6Am) layers incompletely mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PCIF1 reconciles its multiple molecular activities — cap m6Am methyltransferase, methyltransferase-independent IRF3/IFN suppressor, WW-domain growth regulator, and the early SPOP/PDX-1 ubiquitination-adaptor role — within a single coherent regulatory logic remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating cofactor binding with substrate selection\", \"Relationship between the SPOP/ubiquitination function and RNA methyltransferase function unexplained\", \"Rules governing transcript stabilization vs destabilization by m6Am undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [5, 6, 7, 10, 11]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [6, 10, 11]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [10, 20]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2, 8]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [6, 8, 12, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 9, 14, 21, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 13, 17, 24, 25]}\n    ],\n    \"complexes\": [\n      \"PCIF1-CTBP2 complex\",\n      \"PCIF1-SERBP1 complex\"\n    ],\n    \"partners\": [\n      \"RNA Pol II (POLR2A CTD)\",\n      \"PDX-1\",\n      \"CTBP2\",\n      \"SERBP1\",\n      \"G3BP\",\n      \"Vpr (HIV)\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}